首頁 > 市場調查報告書 > 醫療設備

生技設備

細胞解離市場規模，佔有率及趨勢分析:各產品，各組織，各類型，各終端用戶，各地區展望，競爭策略，至2030年的各市場區隔預測

市場調查報告書

商品編碼

1089964

細胞解離市場規模，佔有率及趨勢分析:各產品，各組織，各類型，各終端用戶，各地區展望，競爭策略，至2030年的各市場區隔預測

Cell Dissociation Market Size, Share & Trends Analysis By Product, By Tissue, By Type, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日期: 2022年06月14日 | 出版商:

SPER Market Research Pvt. Ltd. | 英文 208 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球細胞解離的市場規模，預計今後以13.5％的年複合成長率擴大，至2030年達到8億8,148萬美元。細胞為基礎的研究變得繁盛，製藥公司和生物科技企業數量增加，成為市場擴大的要素。

本報告提供全球細胞解離市場相關調查，市場概要，以及各產品，各組織，各類型，各終端用戶，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

Abeomics
AcceGen
Alstem
Becton
Biological Industries
Capricorn Scientific
Central Drug House
Cytiva
Dickinson and Company
Gemini Bio
Genlantis
Innovative Cell Technologies
Miltenyi Biotec
Neuromics
PromoCell GmbH
Roche Diagnostics
STEMCELL Technologies
Thermo Fisher Scientific
VitaCyte
Worthington Biochemical Corporation

簡介目錄

Product Code: BIOT2230

Global Cell Dissociation Market projected to be worth USD 881.48 million by 2030.

According to SPER Market Research, the Cell Dissociation Market estimated to reach USD 881.48 million by 2030 with a CAGR of 13.5%. Growing occurrence of cell-based research, the growing figure of pharmaceutical and biotechnology companies; these are the fuel to the expansion of the market.

Impact of COVID-19 on the Cell Dissociation Market

The outbreak of COVID-19 has a positive impact on the growth of the market.

Scope of the report:

Market size available for years: 2019-2030

Base year considered: 2021

Forecast period: 2022-2030

Segments covered: By Product, By Tissue, By type, By End-User, By Region

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered: Abeomics, AcceGen, Alstem, Becton, Biological Industries, Capricorn Scientific, Central Drug House, Cytiva, Dickinson and Company, Gemini Bio, Genlantis, Innovative Cell Technologies, Miltenyi Biotec, Neuromics, PromoCell GmbH, Roche Diagnostics, STEMCELL Technologies, Thermo Fisher Scientific, VitaCyte, Worthington Biochemical Corporation

Driver:

Increasing research & development activities in biopharmaceutical companies, encouraging funding scenario for cancer research, growing occurrence and incidence of chronic and infectious diseases, growing focus on personalized medicine, growing government funding for cell-based research; are the key drivers for the market expansion.

Restraint:

Costly cell-based researches, short of of infrastructure for cell-based research in emerging economies, can restraint the expansion of the market.

Opportunity:

Growth opportunities in emerging markets, development in stem cell research, appearance of advanced tissue dissociation enzyme products, recognition of enzyme-free dissociation products over enzymatic dissociation products.

Challenges:

Survival of small players and new entrants, ethical concerns regarding research in cell biology, are the challenges of the market.

Global Cell Dissociation Market, By Product:

Based on the Product, Global Cell Dissociation Market is segmented as; Enzymatic Dissociation Products (Collagenase, DNase, Elastase, Hyaluronidase, Papain, Trypsin), Enzymatic Dissociation Products, Instruments.

Global Cell Dissociation Market, By Tissue:

Based on the Tissue, Global Cell Dissociation Market is segmented as; Connective Tissues, Epithelial Tissues, Other type tissues (skeletal and muscles tissues).

Global Cell Dissociation Market, By Type:

Based on the Type, Global Cell Dissociation Market is segmented as; Cell detachment, Tissue dissociation.

Global Cell Dissociation Market, By End-User:

Based on the End-User, Global Cell Dissociation Market is segmented as; Pharmaceutical and Biotechnology companies, Research and Academics, other end users.

Global Cell Dissociation Market, By Region:

North America owns the biggest share of the market; this is due to the concentration of giant companies and growing research in Pharma and biopharma companies.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Cell Dissociation Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Cell Dissociation Market, By Product, 2019-2030 (USD Million)

6.1. Enzymatic Dissociation Products
- 6.1.1. Collagenase
- 6.1.2. DNase
- 6.1.3. Elastase
- 6.1.4. Hyaluronidase
- 6.1.5. Papain
- 6.1.6. Trypsin
6.2. Enzymatic Dissociation Products
6.3. Instruments

7. Global Cell Dissociation Market, By Tissue, 2019-2030 (USD Million)

7.1. Connective Tissues
7.2. Epithelial Tissues
7.3. Other type tissues (skeletal and muscles tissues)

8. Global Cell Dissociation Market, By Type, 2019-2030 (USD Million)

8.1. Cell detachment
8.2. Tissue dissociation

9. Global Cell Dissociation Market, By End-User, 2019-2030 (USD Million)

9.1. Pharmaceutical and Biotechnology companies
9.2. Research and Academics
9.3. other end users

10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)

10.1. North America
- 10.1.1. United States
- 10.1.2. Canada
- 10.1.3. Mexico
10.2. Europe
- 10.2.1. Germany
- 10.2.2. United Kingdom
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Australia
- 10.3.5. South Korea
- 10.3.6. Rest of Asia-Pacific
10.4. South America
- 10.4.1. Brazil
- 10.4.2. Argentina
- 10.4.3. Rest of South America
10.5. Middle East & Africa
- 10.5.1. Kingdom of Saudi Arabia
- 10.5.2. United Arab Emirates
- 10.5.3. Rest of Middle East & Africa

11. Company Profiles

11.1. Abeomics
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. AcceGen
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Alstem
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Becton
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Biological Industries
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Capricorn Scientific
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Central Drug House
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Cytiva
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Dickinson and Company

Company details

Financial outlook

Product summary

Recent developments

11.10. Gemini Bio
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Genlantis
- 11.11.1. Company details
- 11.11.2. Financial outlook
- 11.11.3. Product summary
- 11.11.4. Recent developments
11.12. Innovative Cell Technologies
- 11.12.1. Company details
- 11.12.2. Financial outlook
- 11.12.3. Product summary
- 11.12.4. Recent developments
11.13. Miltenyi Biotec
- 11.13.1. Company details
- 11.13.2. Financial outlook
- 11.13.3. Product summary
- 11.13.4. Recent developments
11.14. Neuromics
- 11.14.1. Company details
- 11.14.2. Financial outlook
- 11.14.3. Product summary
- 11.14.4. Recent developments
11.15. PromoCell GmbH
- 11.15.1. Company details
- 11.15.2. Financial outlook
- 11.15.3. Product summary
- 11.15.4. Recent developments
11.16. Roche Diagnostics
- 11.16.1. Company details
- 11.16.2. Financial outlook
- 11.16.3. Product summary
- 11.16.4. Recent developments
11.17. STEMCELL Technologies
- 11.17.1 Company details
- 11.17.2 Financial outlook
- 11.17.3 Product summary
- 11.17.4 Recent developments
11.18. Thermo Fisher Scientific
- 11.18.1. Company details
- 11.18.2. Financial outlook
- 11.18.3. Product summary
- 11.18.4. Recent developments
11.19. VitaCyte
- 11.19.1. Company details
- 11.19.2. Financial outlook
- 11.19.3. Product summary
- 11.19.4. Recent developments
11.20. Worthington Biochemical Corporation
- 11.20.1. Company details
- 11.20.2. Financial outlook
- 11.20.3. Product summary
- 11.20.4. Recent developments